Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amicus Therapeutics (NQ: FOLD ) 9.800 -0.120 (-1.21%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Amicus Therapeutics < Previous 1 2 Next > Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product June 04, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates May 09, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference May 08, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024 May 01, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report March 20, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024 March 01, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates February 28, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024 February 15, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™ February 08, 2024 - Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease - From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024 February 01, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Time to buy these 3 healthcare companies that raised revenue guidance? January 16, 2024 The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. Via MarketBeat Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook January 07, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO December 05, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates November 08, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023 November 01, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023 October 27, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023 October 03, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration October 02, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease September 28, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023 September 01, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023 August 29, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer August 21, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom August 15, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates August 08, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023 July 31, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union June 27, 2023 Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD) From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates May 10, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference May 02, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.